Sionna falls after experimental drug misses mid-stage trial goal
BUZZ-Sionna falls after experimental drug misses mid-stage trial goal ** Shares of biotech firm Sionna Therapeutics SION.O shares plunge 92% to $3.99 premarket
** Co says experimental cystic fibrosis drug SION-719 failed to improve sweat chloride levels, a key measure of CFTR protein function, in a mid-stage study
** Co says SION-719 will not advance as an add-on treatment to Vertex's standard therapy Trikafta after missing the study's main activity goal
** Trial showed a placebo-adjusted sweat chloride change of -1.0 mmol/L, with potential confounding factors under review
** Sionna says SION-451 dual combinations met safety, tolerability and drug exposure goals in healthy volunteers; reviewing next steps
** Cystic fibrosis is an inherited disease that causes thick, sticky mucus to build up in the lungs and other organs
** As of last close, stock up ~24% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Sionna Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial
Sionna hits record low after experimental drug misses mid-stage trial goal
Vertex Pharma rises after rival genetic disorder drug setback